Far-Infrared Therapy for the Effect of Alzheimer Disease Dementia

Inclusion Criteria: 1. Diagnosed with Alzheimer's disease dementia. 2. Mini-Mental State Examination (MMSE) score between 18 and 24 (inclusive). 3. Currently prescribed and maintained on a stable regimen of anti-dementia medication. 4. No sensory deficits or impairment regarding skin temperature perception. 5. Patient or a Legally Authorized Representative (LAR) must be willing and capable of providing written informed consent prior to enrollment. Exclusion Criteria: 1. Non-Alzheimer's disease dementia (e.g., vascular dementia, Lewy body dementia, frontotemporal dementia). 2. Known hypersensitivity to heat or light, including the current use of photosensitizing medications. 3. Diminished thermal or heat sensitivity, such as from the concurrent use of analgesics, sedatives, or consumption of alcoholic beverages. 4. Acute injury or acute localized inflammation, including active inflammation, infection, or ulcerated wounds. 5. Concomitant acute venous thrombosis, varicose veins, severe peripheral arterial occlusive disease (Stage III or IV), lymphatic disease, acute rheumatoid arthritis, acute gout, or active fever. 6. Presence of mottled erythema or other abnormal dermatological conditions on the scalp or neck. 7. Localized skin lesions, damage, or open wounds at the device contact sites. 8. Concurrent participation in any other clinical trial. 9. Any other underlying pathological conditions or clinical statuses that, based on medical consensus, would preclude safe participation in the study. 10. Failure or refusal to provide signed informed consent. 11. Inability or unwillingness to comply with the trial protocols, schedules, or required follow-up evaluations. 12. History or presence of hemorrhagic disorders or bleeding-related diseases.